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1. Introduction
The enormous field of this topic is clearly shown by the following facts: during the last 10 years 
(2007–2016), around 500 scientific papers/year and 523 review articles were listed in the 
PubMed database on capsaicin, and over 200/year are under keywords of “capsaicin human.”
Recently, two major studies on the mortality of subpopulations consuming spicy food con-
taining capsaicin and nonconsumers showed a significant reduction of death in favor of 
capsaicin consumption. The two cohort studies were made in China [1] and in the USA [2]. 
In the study on Chinese population over 350,000 men and women aged 30–79 with heart 
disease, cancer and stroke at baseline over 3.5 million person-years (2004–2013) the relative 
risk in total mortality was reduced significantly by 14% in the population who ate spice food 
6–7 days/week as compared to those who ate only once/week. The population enrolled was in 
10 diverse geographic areas of China.
In the USA more recently the effect of consumption of hot chili pepper of apparently healthy 
population mortality was surveyed in 16,179 participants during over 270,000 person year 
(follow up median 18.9 years). Out of a total nearly 5000 deaths, the hazard rate was sig-
nificantly reduced by 13% in the population which consumed regularly hot red chili pepper. 
Although in this study published few weeks ago, the mechanism by which hot chili peppers 
reduced mortality was not analyzed. The beneficial effect of chili pepper of the diet (raised 
already much earlier) has been strongly supported.
The spicy hot ingredient of chili pepper is capsaicin, and its similarly active derivatives are 
called capsaicinoids. The site of action of capsaicin on sensory nerve terminals has been 
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identified and the membrane protein of “capsaicin receptor” being a cation channel was 
cloned in 1997 and is now denoted also on structural ground TRPV1.
Recently, within the book series of Progress in Drug Research, the 68th volume deals for the 
first time on “Capsaicin as a Therapeutic Molecule” [3].
Meta-analysis of human studies suggests that capsaicin could be a new approach in treatment 
obesity promoting negative energy balance, increasing fat oxidation and the reduction of ad 
libitum energy intake [4]. This conclusion is strongly supported over a decade. However, we 
have to notify that 627 papers were collected, but only 9 studies offered scientifically impor-
tant data.
Capsaicin consumption in concentrations equivalent to that which can be detected in moder-
ately spicy foods enhances gastric mucosal blood flow by releasing neuropeptide calcitonin 
gene-related peptide (CGRP) from the sensory receptors of the stomach. It elicits pronounced 
gastroprotective effects both in rats and in humans. Testing in healthy subjects under Good 
Clinical Practice (GCP) condition, the capsaicin (in the range of 200–800 μg/100 ml) dose range 
inhibited gastric basal acid output, decreased the COX-inhibitor indomethacin and induced 
gastric microbleeding or ethanol-induced mucosal damage in healthy human beings.
The beneficial effects of capsaicin have been observed on (1) cardiovascular functions; 
(2) stroke; (3) metabolic homeostasis; (4) autoimmune diseases; (5) obesity; (6) tumor; (7) 
Alzheimer disease; (8) prevention of gastrointestinal mucosal damage produced by nonsteroi-
dal anti-inflammatory compounds; and many other diseases.
The capsaicin actions are dose-dependent, because of small doses (400–1200 ug/day) produce 
preventing actions; however, in higher doses (after desensitization), the beneficial effects dis-
appear. This phenomenon is also well detectable in the pain of humans.
The capsaicin research in animals (in vivo) and in in vitro circumstances (conditions) was in 
extreme progress in the last decades; however, the human observations followed relatively 
slowly than the animal observations.
Of course, the human observations can be carried out on the dependence of respecting many 
(ethical permissions, human rights, laws of human clinical nutrition and human clinical phar-
macology, clinical conditions, education and practice of clinicians, etc.) factors.
It is, however, important that the capsaicin (capsaicinoids) can be used as a modifying sub-
stance on the capsaicin-sensitive afferent nerves during the food consumption and drug 
application; consequently capsaicin (capsaicinoids) is (are) involved in human nutrition and 
human medical drug therapy.
We have been working with capsaicin from the 1980s, involved in both clinical nutrition and 
human drug therapy. The prospective, randomized and multiclinical studies have been car-
ried out (respecting the Good Clinical Practice (GPC) and Helsinki Declaration and its modi-
fications – from the years of 1997. We had to learn many problems of capsaicin therapy from 
that time. Therefore, the editor wants to demonstrate some general problems of capsaicin 
application in human beings or in patients.
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2. Some general problems of human medical therapy with capsaicin
Extremely big extend of reference list dealing with capsaicin in humans. Furthermore, it is 
impossible to clear up the applied doses of capsaicin and the different preparations used in 
these examinations (different extractions, different species, stabilities, many other factors in 
time of plant cultivations, environmental circumstances, applied chemicals, punctual chemi-
cal compositions of capsaicinoids, pesticide residues, fungal residues, etc.).
A new issue of this research started in the last decade when the so-called pure capsaicin 
(obtained from different international trade firms [Sigma-Aldrich and other well-known firms]) 
was used in human observations: by this step the chemical composition of capsaicin became 
clear. Later on, we have to learn that these preparations can be used in classical human therapy 
(from the points of human clinical pharmacology).
3. Drug Master File (DMF)
To receive permission for human use of capsaicin preparations from the National and 
International Regulatory Authorities, we have to present the following details: (1) specification 
of the capsicum species; (2) climatic regulations in places of capsicum cultivation; (3) chemi-
cal treatments of capsicum plants during their cultivation; (4) detailed treatment of capsicum 
plants (their collection, drying, extractions storages, etc.); (5) analytical results supporting 
the chemical composition of the plant origin of capsaicinoids extract; (6) chemical stability of 
natural capsaicin (capsaicinoids); (7) analytical results showing the (possible) contamination of 
natural compounds with organic phosphates, pesticides, fusarium, aflatoxins; (8) international 
certification (including the Food and Drug Administration, FDA) on the capsaicin (capsa-
icinoids) content of the natural preparation. Data of abovementioned facts need to be given by 
internationally accredited laboratories. These data are collected in the Drug Master File (DMF).
The leading chemical trading firms—concerning capsaicin supply—had no DMF for their 
capsaicin preparations. Independently, several trading firms keep the natural capsaicin (cap-
saicinoids) preparation in the market without the exact knowledge on the circumstances of 
cultivation, details of extraction and stability of the product. They have no exact information 
on the quantities of residues of organic phosphates, pesticides, fusariums and aflatoxins in the 
capsaicin (proved by certifications of various internationally accredited laboratories).
According to the observations of Foodnews Environmental Working Group (food-news.
org://www.drgreene.org/body.cfm?xyzpdqabc = 21&detail& ref. = 1920), the most sweet peppers 
are contaminated with more than one pesticide. Pesticides were not found, detected only in 32%, 
and seven pesticides were observed in 1% of tested samples. The samples of sweet bell peppers 
contain acephate, dicophar, dimethoate, diphenylamine, fenvalerate, metalaxyl, methamido-
phos, methomyl, permethrin, malathion, endosulfates, azinophosmethyl and o-phenylphenol, 
which may produce animal carcinogens, birth defects, brain and nervous damage as well as the 
damage of immune system and endocrine system (Report Card www.ewg.org).
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In our case, we found only one capsaicin preparation with the Drug Master File (DMF) from 
India, which was signed by the Food and Drug Administration, USA for orally applicable 
capsaicin (capsaicum) in humans. Along with this preparation, we could not extract exact 
information from the manufacturer on abovementioned data to be incorporated into the DMF.
The National Institute of Pharmacy in Hungary requested additional examinations with this 
natural capsaicin (Capsaicin Natural USP 27) obtained from India on geno- and other toxico-
logical studies due to limited knowledge of circumstances on cultivation, collection, storage, 
stability and preparation. In the literature, some data are provided, supporting the genotoxic 
property of some natural preparations by different researchers. Some positivities were indi-
cated with natural capsaicin on the genotoxicity, and the different researchers suggested that 
these mostly depend on various environmental factors of natural capsaicin, since these were 
negative with synthetic capsaicin.
These requested studies with natural capsaicin obtained from India were: (1) the testing of 
natural capsaicin with reverse mutation assay; (2) the testing of mutagenic effects of natu-
ral capsaicin by the mouse micronucleus test; (3) a 14-day oral average dose range finding 
study with natural capsaicin (30, 60 and 120 mg/kg b.w. or orally 14 days); (4) oral dose range 
including the toxicity study of natural capsaicin in Beagle dogs (0.3–0.6–0.9 mg/kg b.w./day 
orally given for 14 days); (5) a 28-day oral toxicity study of natural capsaicin in rats (placebo, 
5, 15 and 30 mg/kg b.w orally for 28 days); and (6) a 28-day oral toxicity study test in Beagle 
dogs (placebo, 0.1–0.3–0.9 mg/kg b.w. orally for 28 days) (together with capsaicin kinetics) [5].
It needs to be mentioned that the time period of the planned human clinical pharmacological 
study was also 1 month. We had to give the results in the DMF for authorities. These toxico-
logical studies were accepted by the authorities because the studies were done by internation-
ally accredited toxicological institutes. However, if the application of capsaicin is planned for 
a longer time (chronically) then new animal toxicological studies are needed for a longer time 
(generally these studies are done in rats and in Beagle dogs together at least for 6 months).
Sorry to say that no correct chronic toxicological studies exist neither in animals nor in humans. 
It’s true that the capsaicin used in the human nutrition for ages of years of 7000s–9000s (used in 
different forms and in different doses or portions). Furthermore, we have no any concrete knowl-
edge on the environments, chemical contaminations, storages, chemical stabilities, chemical 
components of capsaicin and toxicological aspects of these different capsaicin-containing plants.
Although we participated in clinical pharmacological studies, however, the principle laws of 
capsaicin application are the same in human clinical nutritional studies.
The name of “capsaicin” is generally used in agricultural, medical, physiological and phar-
macological researches; however, this material does not contain uniform chemical entities; the 
name of capsaicin correctly is “capsaicinoids.” The name of “capsaicinoids” covers five ana-
logue (capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin) and two homolog 
(nonanoic acid vanillylamide, decanoic acid vanillylamide) compounds.
The United States Pharmacopeia (USP) describes the list of capsaicins (similar to other pharma-
copeia in different countries) and their definitions, identification, melting range and the content 
of capsaicin, dihydrocapsaicin and other capsaicinoids as follows (USP30-NF25 2006 Edition, 
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pp. 1609); capsaicin contains not less than 90% and more than 110.0% of the labeled percentage 
of total capsaicinoids. The content of capsaicin is not less than 55%, and the sum of content of 
capsaicin plus dihydrocapsaicin should not be less than 15%, all calculated on the dried basis [5].
For the human application of capsaicinoids, we received permission from the National Institute 
of Pharmacy; we had to give the following documentations to the National Institute of Pharmacy: 
(1) expert’s opinion; (2) results of all toxicological studies; (3) chemical stability of the natural 
capsaicin preparation; (4) results of pharmaceutical industrial formulation from the natural cap-
saicin; (5) various permissions from our university; (6) the documentation of health insurance of 
volunteers; (7) preclinical dossiers; (8) documented valid permission on the accreditation of the 
clinical pharmacological unit for human phase I and II examinations (accreditation controlled 
by the National Institute of Pharmacy); (9) exact protocols for human clinical pharmacological 
studies; (10) written information on the planned examinations for the volunteers; (11) request for 
authorization of a clinical trial on medical products for human use to the competent authorities 
and ethical committees in the community; and (12) lists of investigators together with their CV 
and qualifications and data of involved institutes (departments participating in this study) [6].
After taking an overview of the different human observations with capsaicin, then practically, 
we are not able to see these criteria abovementioned.
The different book chapters cover some parts from current observations and the classical 
studies dealing with the details of mechanisms of actions of capsaicin are dominant in the 
preclinical studies.
We can see new results on the cultivation procedures of capsaicin from capsicum plants, emerg-
ing technologies to improve capsaicin delivery, correlations between the capsaicinoid divers-
ability and its human food preference, new results on correlation between beneficial effects of 
capsaicin in metabolic diseases (lipid metabolism) and predictors used in treatment response 
to capsaicin. The results of these observations clearly indicate that the capsaicin research for-
warded to the direction of human medical treatment with capsaicin in the last decade.
The evaluation of effectiveness and safety of chemically produced compound(s) are very 
strictly regulated testing programs both in animals and humans.
After a very careful and critical overview of plant origin compounds, it was very surprisingly to see 
health and scientific requirements differ so much in regard to their application as dietary compo-
nents (Response to EMEA Document CPMP/QWP/2819/00 REV 1 AKA EMEA/CVMP/814/00 REV 
1. Guideline on Quality of Herbal Medical Products/Traditional Medicinal Products [Released 21 
July 2001/Consultation Date 30 September 2005]) and as a drug therapy (this Notice to Applicants 
[NTA] prepared by the European Commission consultation with the authorities of the member 
states, the European Medicines Agency and interested parties in order to fulfill the Commission’s 
obligations with respect to Article 6 of Regulation [EC] No. 726/ 2004, and with respect to the 
Annex 1 to obligations amendment [Directive 2003/63/EC as amendment. Directive 2003/63/EC, 
0 J L 159 27.6.2003 p.46 NTA, Vol 2B-CTD, foreword & introduction, edition June 2006]).
I, as the author of this introductory chapter, could not understand the extremely high number 
of applications of plant origin compounds needed for foods, food additive agents, health mod-
ification compounds and classical drugs (especially orally applicable preparations). A lot of 
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chemical compounds are used during the cultivations of different plants (as capsicum spices), 
which are used as sources of various compounds of food and drug preparations. Furthermore, 
during the preparation of the cultivated plants are treated with different chemicals to result 
aimed chemical compounds (we can use “Drug Mas Master File, DMF”, surprisingly up to 
now no “Food Master File, FMF” These aspects are now under the discussion in our days.).
The primary aims of this book were to give an actual cross-sectional research in the field of 
human capsaicin treatments with capsaicin. We hope very much that we gave a good cross 
section from this field in our days.
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